Loading...
Yestar Healthcare Holdings Company Limited
2393.HK•HKSE
Healthcare
Medical - Devices
HK$0.19
HK$0.007(3.87%)

Financial performance has remained strong, with revenue growing from $1.97B in Q2 2022 to $1.27B in Q2 2024. Gross profit continued to perform well, with margins at 17% in the latest quarter. Operating income reached $51.73M in Q2 2024, holding a steady 4% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $75.35M. Net income rose to $1.09B, keeping EPS at $0.47. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan